Results 151 to 160 of about 26,349 (219)

Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography. [PDF]

JACC Case Rep
Polizzi R, Canciello G, Ordine L, Lombardi R, Esposito G, Losi MA.   +5 more
europepmc   +1 more source

Subsarcomeric regulation of thin and thick filaments in skeletal muscle myofibrils. [PDF]

Proc Natl Acad Sci U S A
Sliogeryte K, Fusi L.
europepmc   +1 more source

Severe obesity in human HFpEF alters contractile protein function and organization. [PDF]

Science
Jani VP, Rhodehamel M, Fenwick AJ, Ma W, Fisher E, Giannakopoulos MT, Moon S, Castillo RL, Kennedy LM, Irving TC, Tardiff JC, Murphy E, Chaerkady R, Wang Q, Barry ME, Hahn VS, Sharma K, Margulies KB, Bedi KC, Cammarato A, Kass DA.   +20 more
europepmc   +1 more source

Pharmacologic therapies for hypertrophic cardiomyopathy: The past, the present, and the future. [PDF]

JRSM Cardiovasc Dis
Halațiu VB, Cozac DA, Scridon A.
europepmc   +1 more source

Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy-a case of targeted therapy beyond left ventricular outflow tract obstruction. [PDF]

Front Med (Lausanne)
Yang L, Dai H, Rong Y.
europepmc   +1 more source

Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten. [PDF]

JACC Case Rep
Kitai T, Zhang J, Saku K.
europepmc   +1 more source

Hypertrophic Obstructive Cardiomyopathy Present as Acute Myocardial Infarction in a Nonagenarian. [PDF]

JACC Case Rep
Wan X, Zhan Y, Gao Z, Sui Y, Ren J, Chen H, Chang Y, Zhang C, Wang Y.   +8 more
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

Mavacamten in Obstructive Hypertrophic Cardiomyopathy and C282Y Homozygous Hereditary Hemochromatosis: A First-in-Human Report. [PDF]

JACC Case Rep
Sam R, Ananthaneni A, Planek MI, Kogan A, Gordon R.   +4 more
europepmc   +1 more source

Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis. [PDF]

Arch Med Sci Atheroscler Dis
Hazique M, Lohana S, Kafle S, Bhinder J, Patel KN, Basit J, Bahar AR, Kvapil J, Alraies MC.   +8 more
europepmc   +1 more source